ClinicalTrials.gg
Active, not recruitingNCT05997381REinForceUpdated Oct 26, 2026

BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears

An interventional study of Arthroscopic rotator cuff repair with BioBrace® Implant augmentation. and Arthroscopic rotator cuff repair in Rotator Cuff Tears, sponsored by CONMED Corporation. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by CONMED Corporation · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 168 studies in Rotator Cuff Injuries with a site in United States — 40 open to participants now, 50 under way, none of them phase 3. Rotator Cuff Injuries · United States.

Planned enrollment
4th of 130
268 · median 60
Started
2024
with 10 others
No phase
86 of 168
21 open now
Primary completion
2027-05
later than 26 of 49 live
Registered
136th of 168
by date

Among the 168 studies in Rotator Cuff Injuries with a site in United States, this one is the 4th largest by planned enrollment of the 130 interventional ones that give a count, is one of 11 that started in 2024, is one of 86 with no phase, reaches primary completion later than 26 of the 49 other live ones, and was the 136th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

40 of the 168 studies in Rotator Cuff Injuries with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Rotator Cuff Injuries with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and effectiveness of arthroscopic rotator cuff repair augmented with the BioBrace® Implant vs. arthroscopic rotator cuff repair alone in subjects requiring surgical intervention for a full-thickness rotator cuff tear.

Read the detailed description

This is a prospective, single blind, multi-center, randomized, controlled, pivotal clinical study investigating the treatment of full thickness tears of the rotator cuff. Tears must involve the supraspinatus and/or infraspinatus tendons and measure ≥ 2 cm and \< 5 cm. Subjects meeting the inclusion/exclusion criteria will be enrolled and will undergo either arthroscopic rotator cuff repair augmented with the BioBrace® Implant or arthroscopic rotator cuff repair alone. Clinical evaluations will be conducted at baseline (pre-operatively) and at 6 weeks, 3-, 6-, and 12-months post-operatively using various patient-reported outcome measures and MRI to assess repair integrity and re-tear rate.

03

Conditions studied

  • Rotator Cuff Tears

Browse trials for

Keywords

  • Rotator cuff tear
  • Full thickness tear
  • BioBrace
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 40 to 70 years old
  2. Positive diagnostic imaging by MRI within 6 months of enrollment of the index shoulder indicating a full thickness rotator cuff tear (RCT):

    1. Tear of the supraspinatus and/or infraspinatus tendons
    2. Tear size ≥ 2 cm and \< 5 cm
  3. Chronic shoulder pain ≥ 3 months
  4. Failed non-operative treatment of the index shoulder to include one or all of the following:

    1. Oral analgesics
    2. Nonsteroidal anti-inflammatory medications (NSAIDs)
    3. injections
    4. Activity modifications
    5. Physical therapy or home-guided exercises
  5. Able to read and understand the study REB/IRB approved Form (ICF)
  6. Willing to be available to attend each protocol-required follow-up examination

Intraoperative Inclusion Criteria:

  1. Full thickness tear of the supraspinatus and/or infraspinatus tendons
  2. Tear size ≥ 2 cm and \< 5 cm
  3. Able to reapproximate the tendons to cover > 50% of the footprint on the greater tuberosity

Exclusion criteria

Exclusion Criteria:

  1. Previous surgery of the index shoulder one year prior to the study surgery excluding diagnostic arthroscopy
  2. Fatty infiltration of the index shoulder rotator cuff muscle ≥ Grade 3 (Goutallier Score)
  3. Major medical condition that could affect quality of life and influence the results of the study as determined by the Investigator
  4. Oral use or steroid injection within 6 weeks prior to surgery
  5. Active smoker
  6. History of insulin-dependent diabetes
  7. Documented evidence of a history (e.g., liver testing) of drug/alcohol abuse within 12 months of enrollment
  8. to any device materials including collagen of animal origin (bovine type-I), poly-L-lactic acid (PLLA) or polyethylene glycol (PEG)
  9. Presence of an implanted metallic device or other implants that would contraindicate acquisition or inhibit radiologist review of an MRI of the index shoulder
  10. History of claustrophobia that would prevent an MRI of the index shoulder
  11. Females of who are either pregnant or breastfeeding or plan to become pregnant during the course of the study
  12. Currently participating, or plans to enroll in another clinical trial during this study that would affect the outcomes of this study as determined by the Investigator
  13. History of non-compliance with medical treatment or clinical trial participation
  14. The subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.), to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant with protocol required follow-up
  15. Any comorbidity or condition that renders the patient a poor surgical candidate as determined by the Investigator
  16. The subject is receiving prescription narcotic pain medication
  17. The subject currently has an acute infection in the area surrounding the surgical site
  18. Contralateral shoulder condition where rotator cuff repair is scheduled or to be scheduled over the course of this study
  19. The subject's condition represents a worker's compensation case

Intraoperative Exclusion Criteria:

1. Subject requires subscapularis repair other than a repair with a single anchor

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
268 participants (estimated)

Study arms

  • Experimental
    BioBrace Augment Group

    An arthroscopic rotator cuff repair is performed with the BioBrace Implant fixed on top of the repaired tendon using anchors.

    Device: Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.

  • Sham comparator
    Repair Only Group

    An arthroscopic rotator cuff repair is performed using standard surgical procedure.

    Procedure: Arthroscopic rotator cuff repair

Interventions

  • DeviceArthroscopic rotator cuff repair with BioBrace® Implant augmentation.

    An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.

  • ProcedureArthroscopic rotator cuff repair

    An arthroscopic rotator cuff repair is performed using standard surgical procedure.

06

What researchers measure

Primary outcomes

  1. 6 Month Retear Rate

    The between-group difference in radiological incidence (MRI) of a Sugaya Type IV or V full-thickness discontinuity at postoperative Month 6.

    Time frame: 6 months post-op

Secondary outcomes

  1. 12 Month Retear Rate

    The between-group difference in radiological incidence (MRI) of Sugaya Type IV or V full-thickness discontinuity at postoperative Month 12.

    Time frame: 12 months post-op

  2. Single Assessment Numeric Evaluation (SANE)

    Adjusted mean between-group difference in SANE score from baseline to 6 weeks, 3-, 6-, and 12-months post-op

    Time frame: Baseline, 6 weeks, 3-, 6-, and 12-months post-op

  3. Western Ontario Rotator Cuff Index (WORC)

    Adjusted mean between-group difference in WORC score from baseline to 6 weeks, 3-, 6-, and 12-months post-op

    Time frame: Baseline, 6 weeks, 3-, 6-, and 12-months post-op

  4. EuroQOL Five Dimensions Questionnaire (EQ-5D-5L)

    Adjusted mean between-group difference in health-related, quality of life from baseline to 6 weeks, 3-, 6-, and 12-months post-op

    Time frame: Baseline, 6 weeks, 3-, 6-, and 12-months post-op

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for May 2027, 40 months after the start.

Of 252 interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 40 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2026 → May 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Aug 18, 2023
StartActual
Jan 5, 2024
Primary completionEst.
May 2027was Dec 2026
CompletionEst.
Dec 2027was Jun 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 26, 2026
Primary completion
Dec 2026→May 2027
Oct 26, 2026
Study completion
Jun 2027→Dec 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2026→May 2027
    Study completion Jun 2027→Dec 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05997381
Lead sponsor
CONMED Corporation
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
Jan 5, 2024
Primary completion
May 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion